加科思-B绩后涨逾17% 公司中期收入增加至近4570万元

Core Viewpoint - The company achieved significant revenue growth and reduced losses in its latest interim results, leading to a rise in stock price. Financial Performance - The company reported revenue of 45.664 million RMB, compared to zero revenue in the same period last year [1] - The loss attributable to the company's owners was 58.994 million RMB, a year-on-year reduction of 65.1% [1] Key Developments - Revenue growth was primarily driven by milestone payments from the Elysium licensing agreement [1] - The company's clinical candidate HER2-STING iADC, JAB-BX467, is nominated for 2024 H2 and plans to submit an IND application in 2026 [1]